We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Immunochromatographic Test Detects Fecal Parasites

By LabMedica International staff writers
Posted on 15 Feb 2012
A recently developed test that detects three pathogenic protozoal parasites in human stool samples has been evaluated. More...


An immunochromatographic (IC) dip strip test simultaneously detects Cryptosporidium spp, Giardia duodenalis, and Entamoeba histolytica that are known to cause diarrheal disease.

At the University of Zaragoza (Spain) scientists collected 160 stool samples from patients with intestinal discomfort or diarrhea, in which parasitic infections needed to be ruled out. Samples were taken and analyzed by microscopic examination and by different IC tests, from July 2008 to December 2008. Fresh specimens were processed within 24 hours of collection. Besides the IC tests, both enzyme-linked immunosorbent assays (ELISA) and heminested polymerase chain reactions (PCR) were performed. Microscopy and PCR were the “gold standard” reference techniques and the results of the RidaQuick IC triple stool test were compared with those obtained with ELISA and IC single test for the three parasites.

Microscopic examination revealed that 22 samples were diagnosed as positive for Cryptosporidium spp., 31 for Giardia duodenalis, 41 for Entamoeba histolytica/dispar, and 68 had a negative diagnosis for the three parasites. Results of RidaQuick IC tests (R-Biopharm; Darmstadt, Germany) show sensitivities of 70%-72% for Cryptosporidium, 90%-97% for Giardia and 62.5% for Entamoeba histolytica. Specificities for these three protozoa were 93.6%-94.9%, greater than 99% and 96.1%, respectively. In all diagnoses, agreement with microscopy and PCR was over 90%, except in the triple test and microscopy in E. histolytica detection that was 76.3%, due to the inability of microscopy to differentiate E. histolytica from nonpathogenic species such as E. dispar or E. moshkovskii.

The authors concluded that the triple stool immunoassays provide adequate sensitivities and specificities with clinically relevant cost-effectiveness. They can be used in outbreak situations, for screening proposals and for massive assays in endemic areas where a large number of samples must be analyzed or as complementary test for individual diagnosis since the entire test could be performed in 15–20 minutes. The study was published online on January 20, 2012, in the Journal of Clinical Microbiology & Infectious Diseases.

Related Links:

University of Zaragoza
R-Biopharm



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.